Drugs / EuNmCV-5
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05739292 | Feb → May 2023 | meningococcal infection | EuBiologics Co.,Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EuNmCV-5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05739292 ↗ |
| Modality | Vaccine | “EuNmCV-5, a new pentavalent meningococcal vaccine targeting serogroups A, C, W, X, and Y” PMID 39112515 ↗ Aug 2024 |
| Route | Intramuscular | “0.5mL single intramuscular dose on Day 0” NCT05739292 ↗ |